Healthcare Industry News:  Hydroxyapatite 

Biopharmaceuticals

 News Release - May 5, 2006

MIV Therapeutics Establishes U.S. Corporate Headquarters with Opening of New Offices in Atlanta, GA

Company's U.S. Presence Office to Enhance U.S. Research and Business Relationships for Breakthrough Biocompatible Medical Device Coatings

VANCOUVER, British Columbia--(HSMN NewsFeed)--May 5, 2006--MIV Therapeutics (OTCBB:MIVT ; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced the establishment of an official U.S. headquarters with the opening of a new corporate office in Atlanta, GA.

The new office will be dedicated to reinforcing business and research opportunities and relationships in the United States. Its establishment follows the Company's recent appointment of industry authority Dr. Mark Landy, an internationally recognized Wall Street medical device analyst, as the President of MIV Therapeutics, who will be based in the Atlanta office.

"The opening of the Atlanta office expands our operations and capability to bring a robust pipeline of novel therapeutic solutions to the high-growth cardiovascular treatment marketplace," said Alan Lindsay, CEO of MIVT. "In conjunction with Mark's leadership, our new U.S. office will be dedicated to raising our profile and establishing new strategic partnerships that will help us to realize MIVT's full medical, technological, business and financial potential within the United States, North America, and around the world."

MIVT is a developer of unique, ultra-thin biocompatible and polymer-free coatings for vascular stents, internal drug delivery systems and other medical applications. Its first product line will be launched in 2007 and will target the estimated $160 billion marketplace for localized drug delivery technologies.

"This additional base of operations will help MIVT leverage health care relationships on Wall Street and throughout the industry," said Dr. Landy. "We are committed to the further development of the Company's new generation of biocompatible HAp-based coating technologies for drug-eluting stents and other medical devices."

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called Hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.


Source: MIV Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.